Results 281 to 290 of about 195,243 (312)
Some of the next articles are maybe not open access.
Cancer Letters, 2009
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
VOLPE, Gisella +3 more
openaire +3 more sources
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
VOLPE, Gisella +3 more
openaire +3 more sources
Blood, 2011
Predicting response in chronic myeloid leukemia (CML) patients who are offered tyrosine kinase inhibitor (TKI) second-line therapy is vitally important. For younger patients, allogeneic transplantation is still a therapeutic option Thus, physicians need new models to predict the outcome of their patients.
François, Guilhot, Joëlle, Guilhot
openaire +2 more sources
Predicting response in chronic myeloid leukemia (CML) patients who are offered tyrosine kinase inhibitor (TKI) second-line therapy is vitally important. For younger patients, allogeneic transplantation is still a therapeutic option Thus, physicians need new models to predict the outcome of their patients.
François, Guilhot, Joëlle, Guilhot
openaire +2 more sources
Current Hematologic Malignancy Reports, 2019
The marked improvement in clinical outcomes for patients with chronic myeloid leukaemia (CML) can be solely attributed to the introduction of targeted therapies against the fusion oncoprotein, BCR-ABL1. However, patient responses, although generally positive, remain heterogenous.
Shanmuganathan, N., Hughes, T.P.
openaire +4 more sources
The marked improvement in clinical outcomes for patients with chronic myeloid leukaemia (CML) can be solely attributed to the introduction of targeted therapies against the fusion oncoprotein, BCR-ABL1. However, patient responses, although generally positive, remain heterogenous.
Shanmuganathan, N., Hughes, T.P.
openaire +4 more sources
Hurdles Toward a Cure for CML: The CML Stem Cell
Hematology/Oncology Clinics of North America, 2011Chronic myeloid leukemia (CML) is the first cancer in which a genetic alteration was proven to be of pathogenic significance and is considered a disease model for oncogene addiction, targeted therapy, and cancer stem cells (CSCs). The introduction of tyrosine kinase inhibitors (TKIs) resulted in dramatic improvement in response and survival for ...
Paolo, Gallipoli +2 more
openaire +2 more sources
Blood, 2010
In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CML patients, up front in patients presenting with advanced disease, or as planned second-line therapy ...
openaire +2 more sources
In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CML patients, up front in patients presenting with advanced disease, or as planned second-line therapy ...
openaire +2 more sources
Chromosome abnormalities in CML
Baillière's Clinical Haematology, 1987The Ph chromosome is the hallmark of CML, where it is found in more than 90% of the cases. Cytogenetically, it usually results from a t(9;22)(q34;q11). The Ph arises in a stem cell and in chronic phase is found in all haematopoietic cell lineages, although it causes only increased granulopoiesis, and sometimes increased thrombopoiesis; furthermore ...
openaire +2 more sources
Best Practice & Research Clinical Haematology, 2009
Little important progress was made in terms of prolongation of life for patients with chronic myeloid leukaemia (CML) until the advent of interferon-alpha and allogeneic stem cell transplantation in the 1980s. However, in 1998 the introduction of imatinib, the first tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 oncoprotein, has
openaire +2 more sources
Little important progress was made in terms of prolongation of life for patients with chronic myeloid leukaemia (CML) until the advent of interferon-alpha and allogeneic stem cell transplantation in the 1980s. However, in 1998 the introduction of imatinib, the first tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 oncoprotein, has
openaire +2 more sources
Science Translational Medicine, 2017
Combining two BCR-ABL1 inhibitors with nonoverlapping mechanisms of action eradicates CML and prevents recurrence.
openaire +2 more sources
Combining two BCR-ABL1 inhibitors with nonoverlapping mechanisms of action eradicates CML and prevents recurrence.
openaire +2 more sources